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A comparison of topical Phenytoin with Silverex in the treatment
of superficial dermal burn wounds
PMR CARNEIRO, LRJ R WAN YUMA, CA MKONY
Objective: To compare topical diphenylhydantoin (Phenytoin) with silver sulphadiazine/chlorhexidine 
(Silverex) in terms of rate of wound healing, analgesic and antibacterial properties in small to moderate-sized 
(<30% TBSA) superficial dermal (second degree) bum wounds.
Design: A  prospective randomized controlled study.
Setting: Surgical wards, Muhimbili National Hospital from July 2000 to February 2001.
Subjects: Sixty four patients with acute burns, 32 in each group.
Interventions: Study group treated by sprinkling Phenytoin powder and control group by sprinkling Silverex 
powder, on the wounds for 14 days or until the wound epithelialised or was ready for skin grafting. The data 
collected included demographic characteristics of patients, aetiology of burn injury, circumstances of injury, 
site and extent of burns, pus discharge and smell from the wound, pain and discomfort from the wound, 
bacterial cultures of wound swabs, rate of reduction in wound size and outcome of treatment.
Results: The study enrolled 33 male and 31 female patients, 69% being children under five years of age. Hot 
liquids (80%) and open flames (20%) were the only causes of burns. In 97% of patients injury was due to 
domestic accidents. In half of the patients burns involved the trunk, and 52% of all patients had less than 15 % 
total body surface burnt. Pus discharge was recorded in 59% of Phenytoin-treated and 75 % in Silverex-treated 
patients while foul smell was noted in 19% and 31% of cases respectively. There were more negative bacterial 
wound cultures in Phenytoin-than Silverex-treated wounds on day five and day 10 of treatment, the difference 
being statistically significant (p< 0.01 and 0.001 respectively). There' was also a statistically significant 
difference in wound pain in favour of Phenytoin (p< 0.01). There was no statistically significant difference 
in the rate of healing in the two groups.
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Conclusion: Phenytoin is a cheap and easy-to-use medicament, effective in suppressing burn wound bacteria 
and relieving pain thereby promoting healing, and may be advocated for the purpose in resource-scarce 
environments.
Introduction
Burn injuries constitute a major health problem causing 
considerable morbidity and mortality in Tanzania1 and 
around the world.2,3 It is a common surgical problem and 
leading cause of death (20% mortality) in our paediatric 
surgical ward (Morbidity/Mortality report 2000 — 
Muhimbili National Hospital). Mzezewa et a/.4 reported an 
overall mortality of 22% in a three year study at the Harare 
Burn Units. Inappropriate treatment facilities lead to severe 
complications like wound infections and septicaemia, 
anaemia and contracture deformities resulting in prolonged 
hospitalization with enormous economic impact in medical 
cost and loss of time from school and work. Socio-economic 
factors contributing to increased incidence of burns 
especially in children include domestic accidents resulting 
from explosion of cheap kerosene stoves, poor architectural 
design of the kitchen in low-income families and cooking 
on open fires at floor level often in the open where children 
are playing.5,6
While deep, extensive bums are a specific entity requiring 
specialized intensive care, the more common small to 
moderate size superficial dermal (second degree) burns 
can be a major cause of morbidity due to complications. 
Our standard topical burn wound therapy like the use of 
sofratulle gauze dressings, silver sulphadiazine cream/ 
powder (Silverex) have not been very effective in preventing 
complications like wound infections and the average 
hospitalization period has been about three to four weeks.
Diphenylhydantoin (Phenytoin) powder when used 
topically on burn wounds has been found to be very 
effective.7,8 Phenytoin, a hydantoin derivative, was first 
synthesized in 1908, but its anticonvulsant activity was not 
discovered until 1938 when it was used for epilepsy.9 Since 
then it has been employed in the treatment of many 
conditions including cardiac arrhythmias, muscle disorders, 
trigeminal and related neuralgias and other types of pain. 
Recently, Phenytoin has been found to have a distinct 
beneficial role in the biology of wound repair,910 reducing 
pain and promotes healing and is thereby useful in acute 
burns.7,11 Biopsies of the Phenytoin-treated burns showed 
increased fibroblast p ro liferation ,12 increased 
neovascularization and capillary patency, and increased 
collagen content.13 Decreased wound water loss and 
bacterial contamination and infection were also noted. 
Apart from a case of generalized rash in one study14 no 
adverse reactions (including contact dermatitis or other 
manifestations of hypersensitivity or chemical toxicity) 
have been noted.7'14 Given the strong laboratory10,15'17 and 
clinical7,15,18 evidence, a clinical trial to compare topical 
Phenytoin with Silverex on the rate of wound healing, 
analgesic and anti-bacterial properties in small to moderate
size superficial dermal burns in our environment is 
indicated.
Materials and Methods
This was a randomized, controlled, prospective study. The 
study group consisted of 32 patients with small to moderate 
size (10 to 30%) superficial dermal burns treated with 
Phenytoin and the control group consisted of the same 
number of patients treated with Silverex. The latter is an 
antimicrobial agent used commonly as a topical therapy in 
bums and consists of a combination of silver sulphadiazine 
and chlorhexidine hydrochloride. The study was carried 
out in all adult and children surgical wards in Muhimbili 
National Hospital where bum patients are admitted. Patients 
taking oral Phenytoin or hypersensitive to it and those on 
immunosuppressive or steroid therapy were excluded. 
Also not included were pregnant women and subjects with 
any other condition or therapy which might pose a risk to 
the subject.
The bum site was cleaned with normal saline and debrided 
as required each day for 14 days. Dry Phenytoin powder 
and Silverex powder was then sprinkled topically on to the 
wounds in the study and control group respectively. This 
was done daily until complete healing occurred or uniform 
granulation tissue appeared when skin grafting was done. 
Wound swabs were taken on admission, day five, and day 
10 and transported to the Microbiology Laboratory in 
Stuart transport medium on the same day for culture and 
sensitivity.
Patients were interviewed and the burn wounds were 
inspected daily by the same investigator to assess presence 
of discharge (pus) and/or odour and severity of wound pain 
using the analog scale. Children were assessed on how 
comfortable they wdre with the assistance of their parents/ 
guardian. Rate of wound healing was assessed by measuring 
the decrease in size of the wound calculated approximately 
by multiplying the longest vertical and horizontal 
dimensions of the wound. Determination of wound area 
was done on admission (baseline), days three, seven,10 
and 14.
Ethical clearance and patient consent was obtained, the 
results analyzed and subjected to statistical tests (Chi- 
square test for categorical variables and Student t-test for 
means).
Results
The study period was from July 2000 to February 2001 
whereby 64 patients were enrolled, 32 in each group. 
Children under five years were the majority (69%) but 
there was no significant difference in the distribution of
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patients by age in the two groups. Thirty three were males 
and 31 female patients; there was no significant difference 
in the sex distribution. Scalds (from hot liquids) which 
were the majority (80%), and open flames were the only 
causes of burns in the study and a significant difference in 
the distribution of patients according to aetiology (p< 0.01) 
was noted. Nearly all bums resulted from domestic accidents 
(97%). The remainder were due to assault (non-accidental 
injury). In half of the patients the burns were on the trunk 
and the extent of burns ranged from 10 to 24%. In 52% of 
cases it was less than 15%. Both treatment groups were 
comparable regarding extent of burn injury. Pus discharge 
was seen in 67% of all patients, 59% in burn wounds 
treated with Phenytoin and 75% in those treated with 
Silverex but the difference was not statistically significant. 
Foul smell from bum wounds was noted in 25% of all 
patients. There was, however, no statistically significant 
difference in the two groups. Table I shows the burn wound 
bacterial culture results on admission, days five and 10 of 
treatment; two patients in tne Phenytoin group and one in 
the Silverex group were already discharged by the 10th day 
of treatment as their wounds had healed. While there was 
no significant difference on wound cultures between the 
two groups on admission, there were more patients with 
negative wound bacterial cultures in the Phenytoin group 
than in the controls on days five and 10, the difference was 
highly statistically significant (p< 0.01 and p< 0.001 
respectively). Common pathogens isolated in both groups 
included Pseudomonas aeuriginosa, Klebsiella spp., 
Escherichia coli, Proteus spp. and Staphylococcus aureus.
Table I: Burn wound bacterial cultures.
Phenytoin Silverex
Day Swab taken Positive
N
Negative
N
Positive
N
Negative
N
On Admission 13 19 14 18
Day 5 12 20 23 9
Day 10 3 27 15 16
Seventy eight percent of patients in the Phenytoin group 
reported mild or no pain/discomfort compared to 47% in 
the Silverex group (Table II), the difference being 
statistically significant (p < 0.01). Table III correlates 
treatment outcome with aetiology and shows that complete 
healing was observed in all the Phenytoin-treated burns 
due to scalds whereas six patients in the Silverex group 
healed poorly. Overall, seven patients (22%) in the Silverex 
group progressed poorly and had to have their treatment 
changed compared to only one patient (3 %) in the Phenytoin 
group. This difference was statistically significant (p<
0.05).
The average hospitalization period was 14.2 days in the 
Phenytoin group compared to 16.25 days in the Silverex 
group, however, this difference was not statistically 
significant.
Table II: Presence of wound pain/discomfort.
Phenytoin Silverex Total
Pain/discomfort N N N
Moderate-Severe 7 17 24
Mild or None 25 15 40
Total 32 32 64
Table III: Treatment outcome in relation to aetiology.
Phentoin Silverex Total
Treatment Scald Flame Scald Flame
Outcome N N N N N
Complete healing 21 8 24 0 53
Skin grafting 0 2 0 1 3
Poor healing 0 1 6 1 8
Total 21 11 30 2 64
Discussion
Young children were the majority in this study as it only 
included small to moderate size superficial dermal burns 
that often result from hot liquids following domestic 
accidents.1,19,20 The sex distribution was fairly equal thereby 
avoiding gender bias on the outcome of study. Similarly 
the site and extent of burn injury were comparable in the 
study and control groups. Though there was a statistically 
significant difference in aetiology of burns in the two 
groups (p< 0.01), the authors did not feel that this finding 
contributed to bias in the study as the local management of 
superficial dermal burn wounds is the same irrespective of 
its aetiology.
There were fewer cases of pus discharge and foul smell 
from wounds in the Phenytoin group but the difference was 
not statistically significant. However, pus swabs taken 
from the wounds for culture and sensitivity on the fifth and 
10th day of treatment showed a significant reduction in 
wound contamination in the Phenytoin group (p<0.01 and 
p<0.001 respectively) as was also seen in other 
studies.7'14,21'3 The mechanisms by which Phenytoin reduces 
wound bacterial contam ination are not known. 
Improvements in wound pH and local circulation appear 
likely to be responsible.14 In addition, Lodha et al.23 
attributed it to Phenytoin direct antibacterial effect.
Phenytoin-treated patients appeared significantly more 
comfortable and reported less wound pain (p<0.01) 
correlating other studies.8'14,21'4 The local analgesic property 
of topical Phenytoin is thought to be due to its membrane 
stabilizing actions including modulation of ion flux with 
selective depressions of repetitive neuronal activity and 
synaptic transmission.24 Phenytoin analgesic properties 
minimized the need for pain medications. In addition the 
sodium-free Phenytoin has been reported to avoid the 
initial burning sensation on wounds.14
Lodha et a l f  found the healing of second-degree 
burn areas was consistently faster in the Phenytoin
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group (p < 0.001) but this was not evident in this study. 
However, significantly more patients in the Silverex group 
(p < 0.05) had to have their treatment changed as the 
wounds were not healing well. Average hospitalization 
period was two days less in the Phenytoin group as was also 
reported in another study22 thereby reducing hospital 
> admission costs.
Given Phenytoin antibacterial and analgesic properties 
in promoting bum wound healing, as well as its availability, 
-low cost, ease of use and apparent safety, the authors 
fecominend its use as a treatment modality for burn wounds 
especially in developing countries.
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